Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00456716
Status:
COMPLETED
Last Update Posted:
2010-03-04
First Post:
2007-04-03
Brief Title:
Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Sponsor:
Swedish Medical Center
Organization:
Swedish Medical Center
Study Overview
Official Title:
A Phase II Trial of Sorafenib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2010-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Open label study of sorafenib
Detailed Description:
Open label study using oral sorafenib 800 mg daily in any stage III-IV BAC lung cancer and Stage III-IV adenocarcinoma of the lung in nonsmokers less than 100 cigarettes lifetime
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None